Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | MRD evaluation: how, when and for which goal?

Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, discusses the importance of using measurable residual disease (MRD) to guide therapy in multiple myeloma, and further explains how monitoring disease progression with MRD is the best way to ensure that patients are provided with the best treatment approach. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.